Splenic marginal zone lymphomas with peripheral CD5 expression

Haematologica

Volumn 89, Issue 1, 2004, Pages 113-114

  Giannouli, Stavroula ^a   Paterakis, George ^b   Ziakas, Panayiotis D ^a   Anagnostou, Dimitra ^c   Voulgarelis, Michalis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Natl Histoc Ctr Gen Dist Hosp   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

CD5; Splenic marginal zone lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD5 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOSIS; LYMPHOMA; MALE; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD5; B-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA; MALE; SPLENIC NEOPLASMS;

EID: 0842263699     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Franko V, Florena AM, Iannito E. Splenic marginal zone lymphoma. Blood 2003;101:2464-72.
2. Chacon JI, Mollejo M, Munoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648-54.
3. + extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 1996;105:31-7.
4. + low-grade marginal zone B-cell lymphomas with localized presentation. Am J Surg Pathol 1998;22:201-7.
5. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999;111 Suppl 1:S8-12.
6. Khalidi HS, Brines RK, Browne P, Koo CH, Battifora H, Medeiros U. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Mod Pathol 1998;11:983-8.
7. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994;83:1558-62.
8. Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994;84:3828-34.
9. Wortis HH, Teutsch M, Higer M, Zheng J, Parker DC. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc Natl Acad Sci USA 1995;92:3348-52.
10. Hippen KL, Tze LE, Behrens TW. CD5 maintains tolerance in anergic B cells. J Exp Med 2000;191:883-90.
11. Sole F, Salido M, Espinet B, Garcia JL, Martinez Climent JA, Granada I, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica 2001;86:71-7.
12. Dierlamm J. Genetic abnormalities in marginal zone B-cell lymphoma. Haematologica 2003;88:8-12.
13. Gazzo S, Baseggio L, Coignet L, Poncet C, Morel D, Coiffier B, et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. Haematologica 2003;88:31-8.
14. Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginal zone-related neoplasms of splenic and nodal origin. Haematologica 2003;88:80-93.